Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
España S, Ochoa de Olza M, Sala N, Piulats JM, Ferrandiz U, Etxaniz O, Heras L, Buisan O, Pardo JC, Suarez JF, Barretina P, Comet J, Garcia Del Muro X, Sumoy L, Font A. España S, et al. Among authors: ochoa de olza m. Cancer Manag Res. 2020 Oct 16;12:10251-10260. doi: 10.2147/CMAR.S270392. eCollection 2020. Cancer Manag Res. 2020. PMID: 33116879 Free PMC article.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.
García Del Muro X, Gallardo E, García Carbonero I, Laínez N, José Méndez M, Maroto P, Ochoa de Olza M, Puente J, Reynes G, Rubio J, Santander C, Suárez C, Vázquez Estévez S, Castellano D. García Del Muro X, et al. Among authors: ochoa de olza m. Cancer Chemother Pharmacol. 2014 Jun;73(6):1095-107. doi: 10.1007/s00280-014-2413-0. Epub 2014 Feb 16. Cancer Chemother Pharmacol. 2014. PMID: 24531612 Review.
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ, Ghosh M, Canals F, Vidal A, Piulats JM, Matías-Guiu X, Brana I, Muñoz-Couselo E, Garralda E, Schlosser A, Gros A. Lozano-Rabella M, et al. Among authors: ochoa de olza m. Clin Cancer Res. 2023 Jun 13;29(12):2250-2265. doi: 10.1158/1078-0432.CCR-22-3298. Clin Cancer Res. 2023. PMID: 36749875 Free PMC article.
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas O. Jiménez-Valerio G, et al. Among authors: ochoa de olza m. Cell Rep. 2016 May 10;15(6):1134-43. doi: 10.1016/j.celrep.2016.04.015. Epub 2016 Apr 28. Cell Rep. 2016. PMID: 27134180 Free PMC article.
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D. Climent MÁ, et al. Among authors: ochoa de olza m. Eur J Cancer. 2017 Dec;87:30-37. doi: 10.1016/j.ejca.2017.09.028. Epub 2017 Nov 2. Eur J Cancer. 2017. PMID: 29102858 Clinical Trial.
Tumor-Associated Microbiome: Where Do We Stand?
Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Oliva M, et al. Among authors: ochoa de olza m. Int J Mol Sci. 2021 Feb 1;22(3):1446. doi: 10.3390/ijms22031446. Int J Mol Sci. 2021. PMID: 33535583 Free PMC article. Review.
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin CC, Sharma S, Ochoa de Olza M, Varga A, Taylor M, Schellens JHM, Wu H, Sun H, Silva AP, Faris J, Mataraza J, Cameron S, Bauer TM. Naing A, et al. Among authors: ochoa de olza m. J Immunother Cancer. 2020 Mar;8(1):e000530. doi: 10.1136/jitc-2020-000530. J Immunother Cancer. 2020. PMID: 32179633 Free PMC article. Clinical Trial.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Martin-Liberal J, et al. Among authors: ochoa de olza m. Target Oncol. 2017 Apr;12(2):125-138. doi: 10.1007/s11523-016-0471-4. Target Oncol. 2017. PMID: 27995439
35 results